Lecanemab adoption and geographic variation among patients with diagnosis of mild cognitive impairment or Alzheimer's dementia in Medicare fee‐for‐service beneficiaries

Although lecanemab infusion rate was greater than 1% among only 10 states, the therapy adoption rate among the target population is likely higher as the infusion rate denominator included unconfirmed Alzheimer's cases and patients beyond the early disease stage. Continued medical/scientific education plus availability of home infusion and self-injectable delivery formulation are expected to support increasing lecanemab adoption, especially among minority groups.